Test Code ANCA Cytoplasmic Neutrophil Antibodies, Serum
Reporting Name
Cytoplasmic Neutrophilic Ab, SUseful For
Evaluating patients with clinical features of ANCA-associated vasculitis, specifically granulomatosus with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosus with polyangiitis
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
SerumAdditional Testing Requirements
When used for diagnosis, it is recommended that specific tests for proteinase 3 antibodies and myeloperoxidase antibodies be performed first, with additional testing for anti-neutrophil cytoplasmic antibodies only needed in certain circumstances.(3) A testing algorithm based on these recommendations is available. For more information see VASC / Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum.
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.8 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial.
Specimen Minimum Volume
0.4 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 21 days | |
Frozen | 21 days |
Reference Values
<1:4 (Negative)
Day(s) Performed
Monday through Saturday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86036 x2
86037-Titer (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
ANCA | Cytoplasmic Neutrophilic Ab, S | 87427-1 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
3114 | c-ANCA | In Process |
3119 | p-ANCA | 17357-5 |
Interpretation
Positive results for proteinase 3 (PR3) antineutrophil cytoplasmic antibodies (ANCA) by antigen-specific immunoassay and cANCA by indirect immunofluorescence are consistent with the diagnosis of granulomatosus with polyangiitis, in patients with the appropriate clinical presentation.
Positive results for myeloperoxidase-ANCA by antigen-specific immunoassay and pANCA by indirect immunofluorescence are consistent with the diagnosis of microscopic polyangiitis or eosinophilic granulomatosus with polyangiitis, in patients with the appropriate clinical presentation.
Clinical Reference
1. Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020:6(1):71
2. Ramponi G, Folci M, De Santis M, et al. The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies. Autoimmun Rev. 2021:20(3):102759
3. Bossuyt X, Cohen Tervaert W, Arimura Y, et al. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017:13(11):683-692
4. Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81(3):321-326. doi:10.1136/annrheumdis-2021-221796
5. Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):315-320. doi:10.1136/annrheumdis-2021-221795
6. Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):309-314. doi:10.1136/annrheumdis-2021-221794
Report Available
3 to 4 daysMethod Name
Indirect Immunofluorescence (IIF)
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-General Request (T239)
-Renal Diagnostics Test Request (T830)
Testing Algorithm
For more information see:
-First-Line Screening for Autoimmune Liver Disease Algorithm.